73 related articles for article (PubMed ID: 6089828)
1. Different tendencies of changes in hydrolytic enzyme activities in sera from prostatic cancer patients with or without bone metastasis.
Aoyagi T; Wada T; Tanaka T; Hara T; Umeda T; Niijima T; Umezawa H
Biochem Int; 1984 Apr; 8(4):537-43. PubMed ID: 6089828
[TBL] [Abstract][Full Text] [Related]
2. Decreased serum levels of various hydrolytic enzymes in patients with rheumatoid arthritis.
Aoyagi T; Wada T; Tanaka T; Tanimoto K; Aikawa T; Hara T; Umeda T; Niijima T; Umezawa H
Biochem Int; 1984 Apr; 8(4):529-35. PubMed ID: 6089827
[TBL] [Abstract][Full Text] [Related]
3. Relation of blood glucose levels to the changes in plasma levels of various hydrolytic enzymes in diabetic patients.
Aoyagi T; Wada T; Kojima F; Nagai M; Akanuma Y; Akanuma H; Umezawa H
Biochem Int; 1985 May; 10(5):821-7. PubMed ID: 2990478
[TBL] [Abstract][Full Text] [Related]
4. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Tumminello FM; Flandina C; Crescimanno M; Leto G
Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
[TBL] [Abstract][Full Text] [Related]
5. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
6. Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model.
Lowe FC; Isaacs JT
Cancer Res; 1984 Feb; 44(2):744-52. PubMed ID: 6537899
[TBL] [Abstract][Full Text] [Related]
7. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
8. [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
Chen HX; Li HZ; Li HJ; Shi BB; Jin W; Cheng XQ
Zhonghua Wai Ke Za Zhi; 2007 Mar; 45(6):412-4. PubMed ID: 17537330
[TBL] [Abstract][Full Text] [Related]
9. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
Koizumi M; Yonese J; Fukui I; Ogata E
J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
[TBL] [Abstract][Full Text] [Related]
10. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
11. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression.
Hara I; Miyake H; Yamanaka K; Hara S; Kamidono S
Oncol Rep; 2002; 9(6):1379-83. PubMed ID: 12375052
[TBL] [Abstract][Full Text] [Related]
12. [Bone metabolism and phosphorus metabolism in patients with prostate cancer: paracrine and endocrine effects produced by prostate neoplasm].
Satani H; Yamakawa K; Kawamura J; Mori O; Saito K; Kato H; Tochigi H; Sakurai M; Kato T
Hinyokika Kiyo; 1997 Dec; 43(12):849-54. PubMed ID: 9488931
[TBL] [Abstract][Full Text] [Related]
13. Serum enzymes in ovarian carcinoma.
Dobryszycka W; Warwas M; Gerber J; Ujec M
Neoplasma; 1979; 26(6):737-43. PubMed ID: 44348
[TBL] [Abstract][Full Text] [Related]
14. Cholinesterase activities and biochemical determinations in patients with prostate cancer: influence of Gleason score, treatment and bone metastasis.
Battisti V; Bagatini MD; Maders LD; Chiesa J; Santos KF; Gonçalves JF; Abdalla FH; Battisti IE; Schetinger MR; Morsch VM
Biomed Pharmacother; 2012 Jun; 66(4):249-55. PubMed ID: 22560633
[TBL] [Abstract][Full Text] [Related]
15. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
16. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer.
Kanoh Y; Akahoshi T; Ohara T; Ohtani N; Mashiko T; Ohtani S; Egawa S; Baba S
Anticancer Res; 2002; 22(3):1813-7. PubMed ID: 12168874
[TBL] [Abstract][Full Text] [Related]
18. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.
Adler HL; McCurdy MA; Kattan MW; Timme TL; Scardino PT; Thompson TC
J Urol; 1999 Jan; 161(1):182-7. PubMed ID: 10037394
[TBL] [Abstract][Full Text] [Related]
19. Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7.
Medeiros RM; Morais A; Vasconcelos A; Costa S; Pinto D; Oliveira J; Ferreira P; Lopes C
Clin Cancer Res; 2002 Nov; 8(11):3433-7. PubMed ID: 12429631
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
